Saniona AB: Notice of annual shareholders' meeting in Saniona AB (publ)
21 avr. 2017 02h02 HE | Saniona AB
PRESS RELEASE April 21, 2017  The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the annual shareholders' meeting (Sw. årsstämma) to be held at the premises of...
Saniona AB: Saniona obtains research milestone from The Michael J. Fox Foundation for Parkinson's Research
20 avr. 2017 05h01 HE | Saniona AB
PRESS RELEASE April 20, 2017 Saniona, a leading biotech company in the field of ion channels, today announces that it has reached the second research milestone for identifying new drug candidates...
Saniona AB: Saniona erhåller milstolpsbetalning från Michael J. Fox Foundation for Parkinson's Research
20 avr. 2017 05h01 HE | Saniona AB
PRESSMEDDELANDE 20 april 2017 Saniona, ett ledande bioteknikbolag inom jonkanaler, meddelar idag att bolaget har uppnått den andra forskningsmilstolpen för att identifiera nya...
Saniona AB: Sanionas partner Medix ansökan om Fas 3-studie på fetma godkänd
12 avr. 2017 02h02 HE | Saniona AB
PRESSMEDDELANDE 12 april 2017 Saniona, ett ledande bioteknikföretag inom jonkanaler, meddelar idag att den mexikanska tillsynsmyndigheten Cofepris har godkänt Medix ansökan om en klinisk Fas...
Saniona AB: Saniona's partner, Medix, obtains approval to initiate Phase 3 study in obesity
12 avr. 2017 02h02 HE | Saniona AB
PRESS RELEASE April 12, 2017 Saniona, a leading biotech company in the field of ion channels, today announces that the Mexican regulatory authority, Cofepris, has approved Medix's Phase 3 clinical...
Saniona AB: Saniona inleder fas 2a-studien med Tesomet för Prader-Willi Syndrom
03 avr. 2017 02h02 HE | Saniona AB
PRESSMEDDELANDE 3 april 2017 Saniona, ett ledande bioteknikföretag inom jonkanaler, meddelar idag att bolaget har inlett en klinisk fas 2a-studie i Tjeckien och Ungern med Tesomet på patienter...
Saniona AB: Saniona initiates Phase 2a study for Tesomet in Prader-Willi syndrome
03 avr. 2017 02h02 HE | Saniona AB
PRESS RELEASE April 3, 2017 Saniona, a leading biotech company in the field of ion channels, today announces that it has initiated a Phase 2a clinical study in Czech Republic and Hungary for...
Saniona AB: Saniona räknar med att påbörja den planerade fas 2a-studien med Tesomet för Prader-Willi syndrome i Q2 2017
20 mars 2017 03h01 HE | Saniona AB
PRESSMEDDELANDE 20 mars, 2017 Saniona, ett ledande bioteknikföretag inom jonkanaler, lämnar idag en uppdatering om den planerade fas 2a-studien med Tesomet för Prader-Willis Syndrom (PWS). De...
Saniona AB: Saniona expects to initiate the planed Phase 2a study for Tesomet in Prader-Willi syndrome in Q2 2017
20 mars 2017 03h01 HE | Saniona AB
PRESS RELEASE March 20, 2017 Saniona, a leading biotech company in the field of ion channels, today provides an update on the planned Phase 2a study for Tesomet in Prader-Willi syndrome (PWS). The...
Saniona AB: Saniona announces a merger of its spinout company Ataxion with Luc Therapeutics
06 mars 2017 12h00 HE | Saniona AB
PRESS RELEASE March 6, 2017 Saniona, a leading biotech company within ion-channel research, today announces that its spinout company Ataxion has engaged into a merger with Luc Therapeutics Inc....